Preferred Label : loncastuximab tesirine;

CISMeF synonym : loncastuximab tesirine-lpyl;

UNII : 7K5O7P6QIU;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/zynlonta
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
loncastuximab tesirine
loncastuximab tesirine
loncastuximab tesirine
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
zynlonta
orphan drug production
lymphoma, large B-Cell, diffuse
High Grade B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
infusions, intravenous
product surveillance, postmarketing
adult
aged
pregnancy
breast feeding
Genotoxicity
Antineoplastic Antibody-Drug Conjugate
fertility
drug evaluation, preclinical
drug approval
europe

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.